Clin2
NCT07620496Possibly a fitNot yet recruiting

CAN1012 Treatment for Pre-cancerous Mouth Tissue Changes

Oral Epithelial Dysplasia (OED)

Part of Mouth & dental clinical trials.

This study tests a new drug called CAN1012 to treat oral epithelial dysplasia, which are pre-cancerous changes in the mouth lining. The goal is to see if this drug can help prevent these changes from becoming cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
36 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have been diagnosed with oral epithelial dysplasia (abnormal cell growth in your mouth)
  • You are at least 18 years old and able to understand and follow study instructions
  • You are generally healthy enough for the study, as determined by your doctor
  • Your blood counts and kidney/liver function are within acceptable ranges
  • If you can become pregnant, you must use effective birth control during treatment and for 5+ months after your last dose
  • You don't have serious medical or mental health conditions that would make the study unsafe for you

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07090070Not yet recruiting
Treatment study for p53 mutant oral cancer and precancers

This trial tests different treatments for people with oral cancer or precancerous lesions that have a p53 mutation. It aims to find the best approach for early-stage disease to prevent progression.

Vancouver, British Columbia
NCT07408856Not yet recruiting· Phase 1
A trial of CAN1012 for early breast changes (DCIS and LCIS)

This trial tests a new drug called CAN1012 in people with pre-cancerous breast conditions called DCIS or LCIS. It aims to see if the drug can help before invasive cancer develops.

Portland, Oregon
NCT05865028Recruiting· Phase 2
Test drug APG-157 for abnormal mouth tissue

This Phase 2 trial studies whether APG-157 can safely improve abnormal cells in the mouth (dysplasia) or early cancer-like changes (carcinoma in situ). You may be eligible if you have a visible, biopsy-proven lesion and can take oral medication while meeting blood and health requirements.

Miami, Florida
NCT06550050Recruiting
Study of Mouth Precancer and Cancer Features

This study looks at tissue and blood samples from people with mouth conditions that could become cancer or are already cancer. It aims to learn more about these conditions to improve diagnosis and treatment.

Houston, Texas
NCT05069857Recruiting· Phase 2
New pre-surgery treatment tailored to cancer markers in mouth cancer

This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.

Shanghai, Shanghai Municipality
NCT07579507Not yet recruiting
Understanding Oral Cancer Development: Tissue Study

This research study examines how oral cancer develops by collecting tissue samples from people with oral cancer or pre-cancerous mouth conditions. The goal is to understand what changes happen in the mouth that lead to cancer, which may help improve diagnosis and treatment in the future.

Lyon

Hear when a new Oral Epithelial Dysplasia (OED) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.